HIV and HCC in Africa: The H2A Consortium

非洲的艾滋病毒和肝癌：H2A 联盟

• 批准号: 10471411
• 负责人: Gregory D Kirk
• 金额: $ 99.06万
• 依托单位: JOHNS HOPKINS UNIVERSITY
• 依托单位国家: 美国
• 财政年份: 2020
• 资助国家: 美国
• 起止时间: 2020-09-09 至 2025-08-31
• 项目状态: 未结题
• 来源: https://reporter.nih.gov/project-details/10471411
• 关键词: Address; Adopted; Advocate; Africa; Africa South of the Sahara; African; Age; Aging; Award; Biological Markers; Cause of Death; Chronic; Clinical; Clinical Data; Clinical Research; Collaborations; Country; Data; Development; Epidemiology; Etiology; Foundations; Funding; Goals; HIV; HIV Infections; Hepatitis B; Hepatitis B Infection; Hepatitis B Therapy; Hepatitis B Virus; Hepatitis C virus; Hepatocarcinogenesis; Human; Immune response; Incidence; Individual; Infection; Infrastructure; Intercept; Interruption; Intervention; Investigation; Investments; Lead; Liver; Liver Fibrosis; Liver diseases; Malignant Neoplasms; Measurement; Medical; Mentors; Monitor; Oncogenes; Pathway interactions; Patients; Persons; Pilot Projects; Population; Population Research; Praziquantel; Prevention strategy; Primary carcinoma of the liver cells; Process; Prospective cohort; Research; Research Design; Research Infrastructure; Research Personnel; Research Project Grants; Resource-limited setting; Resources; Risk; Risk Factors; Schistosoma mansonii infection; Senegal; Serum Albumin; Translational Research; Uganda; United States National Institutes of Health; Universities; Viral hepatitis; antiretroviral therapy; base; biobank; biomarker discovery; career development; chronic infection; co-infection; cohort; curative treatments; data quality; design; effective therapy; high risk; improved; innovation; mortality; multidisciplinary; novel; novel marker; predictive marker; prevent; prospective; recruit; response; scale up; screening; success; translational study; treatment strategy

Hepatocellular carcinoma (HCC) is a very common and lethal cancer in Africa, and as patients with HIV live longer, the HCC burden may increase. In prior studies, our team identified chronic infection with hepatitis B and C viruses (HBV, HCV), HIV and Schistosomiasis mansoni as independent risk factors for HCC. Compared to the US, HCC in sub-Saharan Africa occurs at younger age and more advanced stage with survival of only months. Proposed is an East and West African partnership between colleagues at Makerere University in Uganda, Fann University in Senegal and Johns Hopkins University focused on HIV and hepatocellular carcinoma (HCC) in Africa: The H2A Consortium. Building on long-standing collaborative research, mentoring and clinical activities in both countries, our overarching goal is to reduce the heavy burden of HCC in sub- Saharan Africa. We advocate investigating cancer interception strategies using appropriate medical treatments to interrupt or reverse the impact of these HCC-causing infections. We will accomplish this objective by developing local capacity and performing important research. Consortium activities are designed to enhance both the clinical, population and translational research infrastructure and individual African investigator capacity to conduct high-level, collaborative investigation of HIV, chronic infections and HCC. First, we will form a large, prospective cohort of HBV and HBV/HIV co-infected persons to define who needs HBV treatment, determine clinical responses, and characterize breakthrough HCC, while investigating novel biomarkers. To understand our data demonstrating synergistic interaction between chronic HBV and Sm infections, we will examine HBV clinical and immunological responses in the periphery and the liver in response to Sm treatment. HIV is investigated as a key modifier of these relationships in both projects. Integrated within our scientific agenda, early-stage African investigators will be provided mentoring and career development support while conducting a collaborative pilot project leveraging Consortium resources. The impact of our integrated research and capacity development activities will be establishment of the H2A Consortium as partnered Centers of Excellence on HIV and HCC in East and West Africa.

肝细胞癌（HCC）在非洲是一种非常常见和致命的癌症，并且是艾滋病毒感染者的生活